Eurofins CDMO Alphora Partners with UK Company to Develop Revolutionary ADC Manufacturing Platform
核心洞察
Eurofins CDMO Alphora (搜索) has partnered with Daresbury Proteins Ltd. (搜索) to develop a next-generation ADC expression platform that integrates optimized affinity peptide tags directly into monoclonal antibody (搜索) production.
The innovative platform aims to streamline ADC manufacturing by eliminating several traditional conjugation and purification steps, reducing complexity and costs while accelerating development timelines.
The project receives funding and advisory services from Canada's National Research Council Industrial Research Assistance Program to advance targeted therapeutic production capabilities.
Eurofins CDMO Alphora (搜索) announced a strategic collaboration with UK-based Daresbury Proteins Ltd. (搜索) to develop a transformative next-generation antibody-drug conjugate (ADC) expression platform, supported by funding and advisory services from the National Research Council of Canada Industrial Research Assistance Program (搜索) (NRC IRAP).
Novel Expression Platform Streamlines ADC Production
The NextGen ADC Platform: Engineering High Yielding Expression Vectors and Peptide Linker Tags for Advanced ADC Production initiative represents a groundbreaking approach to ADC manufacturing. The platform integrates optimized affinity peptide tags directly into monoclonal antibody (搜索) (mAb) production, fundamentally changing how these complex therapeutics are manufactured.
By engineering peptide tags into the expression system itself, the platform eliminates several traditional conjugation and purification steps that typically complicate ADC manufacturing. This streamlined approach is designed to reduce manufacturing complexity and costs while significantly accelerating development timelines for targeted therapeutics.
Addressing Growing Demand for Targeted Therapeutics
The collaboration addresses the increasing demand for targeted therapeutics by developing a high-yield expression platform that could transform ADC production capabilities. The initiative aims to establish the foundation for future production of clinic-ready ADCs designed for efficient point-of-care reconstitution, potentially generating significant benefits across both clinical and commercial supply chains.
Strategic Partnership Leverages Complementary Expertise
The partnership combines Eurofins CDMO Alphora (搜索)'s proven capabilities in complex drug development and manufacturing with Daresbury Proteins Ltd. (搜索)'s specialized protein expression technology. Eurofins CDMO Alphora operates an FDA, Health Canada, and Japan PMDA inspected facility in Mississauga, Ontario, with over 250 employees and comprehensive capabilities spanning small molecule APIs, HPAPIs, oral drug products, monoclonal antibodies, proteins, and ADCs.
The collaboration is positioned to drive innovative solutions while fostering highly-skilled job creation and supporting Canada's capacity to produce the next wave of precision biologics. The project represents a significant investment in advancing ADC manufacturing technology to meet the evolving needs of the biopharmaceutical industry.